Trial Search Results

Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990

Wiskott - Aldrich syndrome (WAS) is a rare serious medical condition that causes problems both with the immune system and with easy bruising and bleeding. The immune abnormalities cause patients with WAS to be very susceptible to infections. Depending on the specific type of primary immune deficiency diseases, there are effective treatments, including antibiotics, cellular therapy and gene therapy, but studies of large numbers of patients are needed to determine the full range of causes, natural history, or the best methods of treatment for long term success.

This multicenter study combines retrospective, prospective and cross-sectional analyses of the transplant experiences for patients with WAS who have already received HCT since 1990, or who will undergo Hematopoietic cell transplant (HCT) during the study period. The retrospective and prospective portions of the study will address the impact of a number of pre and post-transplant factors on post-transplant disease correction and ultimate benefit from HCT and the cross-sectional portion of the study will assess the benefit of HCT 2 years post-HCT in consenting surviving patients.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator: Rare Diseases Clinical Research Network

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   - WAS participants will be defined as males who have:

      1. thrombocytopenia (< 100K) AND EITHER molecular diagnosis of WAS OR reduced WASP
      expression; OR

      2. thrombocytopenia (< 100K) AND positive family history consistent with WAS
      diagnosis; OR

      3. chronic thrombocytopenia (< 100K for minimum of 3 months) AND low mean platelet
      volume (MPV below normal range for age) AND EITHER recurrent and/or severe
      infections requiring treatment and/or eczema OR lack of antibody response to
      polysaccharide antigens or low IgM.

   - Longitudinal Analysis (Retrospective and Prospective)

      1. Stratum A. Participants with WAS who have or will Receive HCT

         - Participants with WAS who have received an HCT since January 1, 1990

      2. Stratum B. Participants with WAS who have or will Receive Gene Transfer

         - Participants in which the intention is to treat with gene transfer with
         autologous modified cells

   - Cross-Sectional Analysis (Strata A and B) 1. Participants with WAS who are surviving
   and at least 2 years after the most recent HCT or gene therapy.

Exclusion Criteria:

   - As this is a natural history study, for both the Longitudinal Analysis and the
   Cross-Sectional Analysis we will not exclude any patients due to race or age who fit
   the inclusion criteria.

Ages Eligible for Study

N/A - N/A

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Matthew Porteus, MD
650-725-6520
Not Recruiting